By Josh White
Date: Monday 31 Mar 2025
(Sharecast News) - Bioventix reported a marginal rise in revenue for the six months ended 31 December on Monday, with profit before tax dipping slightly due to higher research and development expenditure.
By Iain Gilbert
Date: Thursday 31 Oct 2024
(Sharecast News) - Bioventix revealed on Thursday that chief financial officer Bruce Hiscock had acquired 333 ordinary shares in the London-listed antibodies development and supply company.
By Josh White
Date: Monday 28 Oct 2024
(Sharecast News) - BioVentix, a UK-based developer of high-affinity monoclonal antibodies for clinical diagnostics, reported a 6% improvement in full-year revenue on Monday, to £13.6m, up from £12.82m in the prior year.
Currency | UK Pounds |
Share Price | 2,483.33p |
Change Today | 8.33p |
% Change | 0.34 % |
52 Week High | 4,400.00p |
52 Week Low | 2,300.00p |
Volume | 5,985 |
Shares Issued | 5.22m |
Market Cap | £129.75m |
Beta | 0.03 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Latest | Previous | |
---|---|---|
1st Interim | 2nd Interim | |
Ex-Div | 10-Apr-25 | 07-Nov-24 |
Paid | 25-Apr-25 | 21-Nov-24 |
Amount | 70.00p | 87.00p |
Time | Volume / Share Price |
12:07 | 130 @ 2,452.00p |
11:54 | 17 @ 2,452.00p |
11:35 | 24 @ 2,452.00p |
11:00 | 2,900 @ 2,480.00p |
11:00 | 800 @ 2,480.00p |
CEO | Peter John Harrison |
Chair | Ian James Nicholson |
CFO | Bruce Hiscock |
You are here: research